Intellipharmaceutics Announces Resignation of Chief Financial Officer
August 08, 2017 15:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit
July 31, 2017 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse-Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
July 26, 2017 20:15 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Second Quarter 2017 Results
July 11, 2017 17:15 ET
|
Intellipharmaceutics International Inc.
TORONTO, July 11, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces FDA Advisory Committee Meeting for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
June 30, 2017 16:05 ET
|
Intellipharmaceutics International Inc.
TORONTO, June 30, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Launch of Generic Seroquel XR® by Mallinckrodt
June 06, 2017 08:50 ET
|
Intellipharmaceutics International Inc.
TORONTO, June 06, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement to Replace Expiring Shelf Registration Statement
May 26, 2017 17:40 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 26, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR® by Par Pharmaceutical
May 24, 2017 16:05 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®
May 10, 2017 15:17 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 10, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Intellipharmaceutics Reports Director Election Results
April 18, 2017 18:15 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 18, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...